Clinical, and political, aspirations about the potential of hydroxychloroquine and chloroquine to become a widespread treatment for COVID-19 continue to decline with the US Food and Drug Administration recommending only limited use of the products.
FDA officials issued a safety announcement on 24 April stating that hydroxychloroquine and chloroquine, either alone or in combination with azithromycin, (Pfizer Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?